Ann: Program Update Anagrelide, page-36

Margaret,

Look at a bit of history in regards to Zolpimist

Developed by Nova Tel

Announcement 8 January 2015

• SUDA grants an exclusive licence to SUD-002 oral spray for Americas and South Africa
• SUDA receives an exclusive global licence (excl. Americas and South Africa) to Zolpimist® oral spray
• Zolpimist® is a patented, fast-acting sedative for insomnia, registered in the USA• Amherst to fund all further development of SUD-002 in the USA

Announcement 10 December 2015

Under the terms of the new agreement, SUDA has expanded its territorial rights to ZolpiMist® to include South America, Central America and South Africa. As a result, SUDA now has a global license, excluding North America, to this US-registered oral spray of zolpidem tartrate for the treatment of insomnia. As per the cross-licensing agreementsigned in January 2015, SUDA will pay Amherst a 6 to 12 per cent share of income from SUDA’s commercialisation of ZolpiMist® in the original territories. In the countries newly added to the licensing agreement with Amherst, the companies will share equally the proceeds from commercialisation of ZolpiMist®.
Business development discussions with prospective partners are progressing in several countries, including in the expanded territory.
SUDA has also regained global rights to SUD-002

The rights then end up with Magna and then to AYTU

So SUDA got the license for their territories for next to nothing - as Amherst handed back the rights of SUD - 002

As for advanced discussions with big pharmas SUDA have been reporting these discussions since 2016 so old news